KA
TEVA icon

Kovack Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Kovack Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,085
Closed -$76K – 552
2019
Q3 		$76K Buy
+11,085
New +$84.9K 0.02% 457

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Kovack Advisors's TEVA Position: Q4 2019 in Review

Kovack Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 11,085 shares — an estimated $76K sold.

Kovack Advisors first reported a position in TEVA in Q3 2019 and held it in 1 quarter. The position peaked at $76K in Q3 2019. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

  • Kovack Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Kovack Advisors sold 11,085 Teva Pharmaceuticals shares in Q4 2019, an estimated $76K.
  • Kovack Advisors first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Kovack Advisors's Teva Pharmaceuticals position peaked at $76K in Q3 2019.
  • 436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Kovack Advisors's 13F filing for Q4 2019, filed 29 Jan 2020.